At the same time, Fang's clinical case reported that in a patient with osimertinib-resistant EGFR G724S/ex19del lung adenocarcinoma, afatinib treatment achieved significant results, indicating that G724S mutant tumors may still be sensitive to afatinib in vivo, which provides a promising therapeutic strategy for patients with such mutations(Fig. 3) [74]. This evidence concerns the gene EGFR and lung adenocarcinoma.